Modification notice
Modification of a contract/concession during its term
Section I: Contracting
authority
I.1) Name and addresses
NHS Blood and Transplant
North Bristol Park
Filton
UK
Contact person: Gabriella Lesca
Telephone: +44 7385387928
E-mail: gabriella.lesca@nhsbt.nhs.uk
NUTS: UK
Internet address(es)
Main address: https://www.nhsbt.nhs.uk
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Supply of Whole Blood Collection System and Ancillary Processing Systems
Reference number: NHSBT0763
II.1.2) Main CPV code
33141613
II.1.3) Type of contract
Supplies
II.2) Description
II.2.1) Title
Whole Blood Collection Systems (Lot 1) and Ancillary Processing Systems (Lot 2)
II.2.2) Additional CPV code(s)
33141630
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
UNITED KINGDOM, IRELAND, AUSTRALIA, and NEW ZEALAND.
II.2.4) Description of the procurement
On the 9 June 2017, this tender (EuroBlood Pack 2) for the supply whole blood and ancillary processing systems was awarded under a framework agreement with the notice number
https://ted.europa.eu/udl?uri=TED:NOTICE:155066-2016:TEXT:EN:HTML with subsequent contract award notice 2017/S 128-260952
https://ted.europa.eu/udl?uri=TED:NOTICE:260952-2017:TEXT:EN:HTML EuroBloodPack 2 was run by NHSBT, working with other European Blood Alliance members (full details of the EBA and their members are available at www.europeanbloodalliance.eu/ updated from time to time), the Australian Blood Service (ARCBS) and New Zealand Blood Service (NZBS)
who were all potential beneficiaries to the agreement. To note, those beneficiaries are eligible to place orders but not mandated EuroBloodPack 2 is divided in two lots respectively:
• Whole Blood Collection System (Lot 1); and
• Ancillary Processing System (Lot 2).
Lot No 1: to supply bottom and top, top and top and dry packs;
Lot No 2: To supply: quadruple transfer system for the storage of platelets for neonatal use, quadruple transfer system for the storage of frozen plasma for neonatal use, quadruple transfer system for the storage of red cells for neonatal use, Sextuplet transfer system for the storage of red cells for neonatal use, single transfer pack for the handling of waste material or storage of plasma components, cryoprecipitate pooling system, plasma filter system — single storage pack, in-process filter system for platelets, Platelet storage system, Platelet pooling filter system, platelet pooling filter system incorporating integral sampling device.
II.2.7) Duration of the contract, framework agreement, dynamic purchasing system or concession
Start:
09/06/2017
End:
31/03/2023
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2017/S 128-260952
Section V: Award of contract/concession
Contract No: NHSBT0763
V.2 Award of contract/concession
V.2.1) Date of conclusion of the contract/concession
09/06/2017
V.2.2) Information about tenders
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor/concessionaire
MacoPharma GMP.b, Haemonetics S.A, Fresenius Kabi Ltd
Mouscron, Runcorn, Signy
UK
NUTS: UK
The contractor/concessionaire is an SME:
No
V.2.4) Information on value of the contract/lot/concession (excluding VAT)
Total value of the contract/lot:
/concession: 70 000 000.00
GBP
Section VI: Complementary information
VI.4) Procedures for review
VI.4.1) Review body
High Courts of Justice
London
UK
VI.5) Date of dispatch of this notice
10/05/2021
Section VII: Modifications to the contract/concession
VII.1) Description of the procurement after the modifications
VII.1.1) Main CPV code
33141613
VII.1.2) Additional CPV code(s)
33141630
VII.1.3) Place of performance
NUTS code:
UK
Main site or place of performance:
UNITED KINGDOM, IRELAND, AUSTRALIA, and NEW ZEALAND.
VII.1.4) Description of the procurement
The EuroBloodPack 2(EBP2) framework agreement has a duration of 4 years and is due to expire on the 9 June 2021. This Modification will extend the EBP2 framework until 31 March 2023.
VII.1.5) Duration of the contract, framework agreement, dynamic purchasing system or concession
Start:
09/06/2017
End:
31/03/2023
VII.1.6) Information on value of the contract/lot/concession (excluding VAT)
Total value of the procurement: 70 000 000.00 GBP
The contract/concession has been awarded to a group of economic operators:
No
VII.1.7) Name and address of the contractor/concessionaire
MacoPharma GMP.b, Haemonetics S.A, Fresenius Kabi Ltd
Mouscron, Runcorn, Signy
UK
NUTS: UK
The contractor/concessionaire is an SME:
No
VII.2) Information about modifications
VII.2.1) Description of the modifications
The EuroBloodPack 2(EBP2) framework agreement has a duration of 4 years and is due to expire on the 9 June 2021. This modification will extend the EBP2 framework until 31 March
2023. Due to the impact of Covid-19 and the support for the Convalescent Plasma (CVP) programme there has been a significant delay in the retendering the new supply and in
Developing the replacement International Blood Pack 1 (IBP1) Framework on time.
VII.2.2) Reasons for modification
Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee
Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:
This Modification Notice is to provide notice that the EBP2 is being modified in accordance with Regulation 72 .1. B and/or 72.1.C of the Public Contracts Regulations 2015. This is because of the continuing focus of the contracting authorities on the Covid-19 crisis (which no diligent contracting authority could have foreseen) has significantly reduced the technical support for a retender. The length of this time has been chosen so that the replacement framework IBP1 can be completed. The length of time of this extension is because any other interim arrangements would be in place for such a short duration that it would cause significant inconvenience and/ or substantial duplication of costs; along with causing significant technical barriers such as requirements of interchangeability or interoperability with existing equipment, services or installations procured under the initial procurement.
VII.2.3) Increase in price
Updated total contract value before the modifications (taking into account possible earlier contract modifications and price adaptions and, in the case of Directive 2014/23/EU, average inflation in the Member State concerned)
Value excluding VAT: 70 000 000.00 Currency: GBP
Total contract value after the modifications
Value excluding VAT: 104 000 000.00 Currency: GBP